EN | UA
EN | UA

Help Support

Back

Effectiveness of Fremanezumab in migraine people refractory to prior preventive medications

Migraine Migraine
Migraine Migraine

During a 12-week double-blind period (DBP) and open-label extension (OLE), a FOCUS phase 3b research examined effectiveness of Fremanezumab in episodic or chronic migraine (EM/CM) people and prior recorded unsuitable response to two to four preventative therapy.

See All

Key take away

In episodic and chronic migraine sufferers refractory to earlier preventative drug classes, Fremanezumab exhibited long-term efficacy.

Background

During a 12-week double-blind period (DBP) and open-label extension (OLE), a FOCUS phase 3b research examined effectiveness of Fremanezumab in episodic or chronic migraine (EM/CM) people and prior recorded unsuitable response to two to four preventative therapy.

Method

Patients were randomly assigned (1:1:1) to receive monthly or quarterly Fremanezumab or a placebo for DBP after a baseline period of 28 days. Patients who successfully completed DBP were admitted to OLE, where everyone was treated with Fremanezumab on a monthly basis. DBP group summarized the results.

Result

Table 1 illustrates the least squares mean changes in monthly migraine days (MMD) in placebo, quarterly, and monthly Fremanezumab groups for CM patients (n=509) and for EM patients (n=328), mean MMD changes for EM patients (n=313) and for CM patients (n=493) during OLE and DBP. For individuals with CM and EM, the monthly headache days of at least moderate severity decreased during DBP and elevated during OLE. For DBP and OLE, ≥50% reduction in MMD in placebo, quarterly, and monthly Fremanezumab groups for CM and EM individuals was observed.

Conclusion

The monoclonal antibody Fremanezumab showed sustained effectiveness in EM and CM people who had unsatisfactory responses to several preventative classes.

Source:

Journal of Neurology, Neurosurgery & Psychiatry

Article:

086 Long-term efficacy of Fremanezumab in migraine patients with inadequate response to prior preventive medication classes

Authors:

Steffen Naegel et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: